Previous 10 | Next 10 |
NEW YORK, Jan. 08, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced the closing of its previously announced registered direct o...
Gainers: Isoray (ISR) +187%.The9 (NCTY) +48%.9 Meters Biopharma (NMTR) +40%.AIkido Pharma (AIKI) +40%.Guardion Health Sciences (GHSI) +38%.TAT Technologies (TATT) +35%.Orchard Therapeutics (ORTX) +35%.Change Healthcare (CHNG) +31%.CleanSpark (CLSK) +30%.CBAK Ener...
PAVmed ([[PAVM]] -13.4%) inks agreement for the sale of 6.0M common stock at $2.24/share, priced at-the-market, in a registered direct offering.Total gross proceeds are expected to be ~$13.4M.Net proceeds from the offering are expected to be ~$12.4M. Maxim Group LLC is acting a...
NEW YORK, Jan. 06, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced it has entered into agreements for the sale of 6.0 mil...
PAVmed (PAVM) declares the closing of previously announced registered direct offering of ~5.1M shares of common stock at $1.60 per share.The company plans to use the net proceeds of ~7.4M for working capital, general corporate purposes, and partial repayment of its outstanding conve...
NEW YORK, Dec. 22, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced the closing of its previously announced registered direct o...
PAVmed ([[PAVM]] -3.6%) entered into agreements for the sale of ~5.1M shares in a registered direct offering with predominantly existing institutional investors at a price of $1.60/share for gross proceeds of $8.1M.Estimated net proceeds are expected to be ~$7.4M; offering expected to close o...
NEW YORK, Dec. 18, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced it has entered into agreements for the sale of approximatel...
PAVmed (PAVM) enters into agreements for the sale of 5.6M shares in a registered direct offering at a price of $1.60 per share for gross proceeds of ~$8.9M.Offering expected to close on or about December 15.Press Release For further details see: PAVmed offers stock for $8.9M
PAVmed, Inc. (PAVM) Q3 2020 Earnings Conference Call November 17, 2020 4:30 PM ET Company Participants Mike Havrilla – Director-Investor Relations Lishan Aklog – Chairman and Chief Executive Officer Dennis McGrath – President and Chief Financial Officer Conference Call Pa...
News, Short Squeeze, Breakout and More Instantly...
Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume PR Newswire Quarterly EsoGuard ® test volume increased 31 percent sequentially NEW YORK , July 23, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("L...
Lucid Diagnostics Launches New Corporate Website PR Newswire NEW YORK , July 11, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-ow...
Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population PR Newswire Prospective screening study demonstrates excellent EsoGuard s...